High-Cost Reserve Antibiotics for Severe and Multidrug-Resistant Infections
The highest-cost antibiotics that should be reserved for severe or multidrug-resistant infections include carbapenems (meropenem, imipenem-cilastatin, doripenem), newer β-lactam/β-lactamase inhibitor combinations (piperacillin-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam), cefiderocol, polymyxins (colistin, polymyxin B), linezolid, daptomycin, and tigecycline.
Carbapenems: Reserve for High-Severity Infections
Carbapenems represent a critical class of expensive broad-spectrum antibiotics. For community-acquired intra-abdominal infections, ertapenem is acceptable for mild-to-moderate cases, but meropenem, imipenem-cilastatin, and doripenem should be reserved exclusively for high-severity infections or those with risk factors for multidrug-resistant organisms 1, 2. The 2024 WHO guidelines specifically classify meropenem as "Watch" category, emphasizing its reserve status 2.
For hospital-acquired pneumonia and ventilator-associated pneumonia with suspected multidrug-resistant pathogens, carbapenems (imipenem 500 mg IV q6h or meropenem 1 g IV q8h) should only be used when patients have risk factors including prior IV antibiotic use within 90 days, septic shock, ARDS, ≥5 days hospitalization, or acute renal replacement therapy 3.
Newer β-Lactam/β-Lactamase Inhibitor Combinations
The newest and most expensive reserve antibiotics include ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, and cefiderocol 4, 5. These agents cost 6-60 times more than older alternatives for MRSA and up to 20 times more for carbapenem-resistant Acinetobacter 6. These should be strictly reserved for confirmed carbapenem-resistant Enterobacterales (CRE), difficult-to-treat resistant Pseudomonas aeruginosa, or carbapenem-resistant Acinetobacter baumannii 5.
Piperacillin-tazobactam, while less expensive than the newest agents, should still be reserved for high-severity community-acquired infections or nosocomial infections requiring antipseudomonal coverage 1, 2. For mild-to-moderate infections, narrower-spectrum agents like ampicillin-sulbactam or cefuroxime plus metronidazole are preferable 1, 7.
Polymyxins: Last-Resort Agents
Polymyxins (colistin and polymyxin B) should be reserved exclusively for settings with high prevalence of multidrug resistance and only where local expertise exists in using these medications 3. These agents require drug level monitoring and dose adjustments. The 2016 IDSA/ATS guidelines specify colistin dosing as 5 mg/kg IV loading dose followed by complex maintenance dosing based on creatinine clearance 3.
Polymyxins should never be used as monotherapy—combination therapy with at least one other active agent is essential, particularly when treating carbapenem-resistant infections 8. The evidence suggests polymyxin-containing regimens benefit most from companion drugs, though specific combinations remain debated 8.
Anti-MRSA Agents: Linezolid and Daptomycin
For methicillin-resistant Staphylococcus aureus (MRSA), linezolid (600 mg IV q12h) and daptomycin represent expensive alternatives to vancomycin 3. Linezolid should be preferred for MRSA pneumonia, while daptomycin (10-12 mg/kg for VRE, 6 mg/kg for MRSA) is indicated for bloodstream infections 5. Daptomycin is specifically recommended for right-sided endocarditis and may be used for left-sided disease 9.
Vancomycin, while less expensive, requires therapeutic drug monitoring and has inferior outcomes compared to these newer agents in certain scenarios 3. However, the significantly higher cost of linezolid and daptomycin mandates their restriction to documented MRSA infections or vancomycin-resistant enterococci 5.
Tigecycline: Limited Reserve Role
Tigecycline should be reserved for specific multidrug-resistant infections, particularly when used in combination therapy for carbapenem-resistant organisms 8. However, tigecycline was excluded from recent WHO recommendations due to FDA boxed warnings regarding potentially higher mortality rates 2. When polymyxin or tigecycline are prescribed, adding a companion drug appears more advisable than monotherapy 8.
Practical Stewardship Approach
Agents that should NOT be routinely used for community-acquired infections include those designed for nosocomial ICU infections 1. The unnecessary use of broad-spectrum agents contributes to resistance emergence and increases costs substantially 1.
For mild-to-moderate community infections, use narrow-spectrum options: ampicillin-sulbactam, cefazolin or cefuroxime plus metronidazole, or ertapenem 1, 2. Reserve broader agents (meropenem, imipenem, piperacillin-tazobactam) for patients with APACHE II scores ≥15, immunosuppression, or inadequate source control 7.
The annual incremental cost of treating difficult-to-treat Gram-negative bacteria with new drugs ranges from $30 million to over $500 million USD 6. This economic burden, combined with limited evidence of superiority over older agents in many scenarios, necessitates strict antimicrobial stewardship protocols requiring infectious disease consultation before prescribing reserve antibiotics 4, 5.